Literature DB >> 3476219

Metabolism of epidoxorubicin in animals: absence of glucuronidation.

P A Maessen, K B Mross, H M Pinedo, W J van der Vijgh.   

Abstract

Metabolism of epidoxorubicin was studied in plasma of seven different animal species at 2 h after administration of 4 mg/kg. None of the animals showed significant glucuronidation of epidoxorubicin, although small amounts of the glucuronides could be detected in the rabbit. However, large differences in formation of epidoxorubicinol and 7-deoxy (7d) doxorubicinol aglycone were observed between the species. These phenomena may be relevant for interspecies differences with regard to anthracycline-induced histomorphological changes in for example, heart tissues and cardiotoxicity in relation to formation of 7d aglycones.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3476219     DOI: 10.1007/BF00252968

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

2.  Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography.

Authors:  H Weenen; A P Osterop; S E van der Poort; J Lankelma; W J van der Vijgh; H M Pinedo
Journal:  J Pharm Sci       Date:  1986-12       Impact factor: 3.534

3.  Adriamycin and daunorubicin disposition in the rabbit.

Authors:  N R Bachur; R C Hildebrand; R S Jaenke
Journal:  J Pharmacol Exp Ther       Date:  1974-11       Impact factor: 4.030

4.  Comparative metabolism and excretion of adriamycin in man, monkey, and rat.

Authors:  P M Wilkinson; M Israel; W J Pegg; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits.

Authors:  M Broggini; B Sommacampagna; A Paolini; E Dolfini; M G Donelli
Journal:  Cancer Treat Rep       Date:  1986-06

6.  Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography.

Authors:  P A Maessen; K B Mross; H M Pinedo; W J van der Vijgh
Journal:  J Chromatogr       Date:  1987-07-03

7.  Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice.

Authors:  W Bolanowska; T Gessner
Journal:  Xenobiotica       Date:  1982-02       Impact factor: 1.908

8.  Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.

Authors:  H Weenen; J M van Maanen; M M de Planque; J G McVie; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1984-07

9.  Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent.

Authors:  C Bertazzoli; C Rovero; L Ballerini; B Lux; F Balconi; V Antongiovanni; U Magrini
Journal:  Toxicol Appl Pharmacol       Date:  1985-07       Impact factor: 4.219

10.  Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).

Authors:  J Cummings; S Merry; N Willmott
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04
  10 in total
  8 in total

1.  The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats.

Authors:  K S Hall; L Endresen; L Schjerven; H E Rugstad
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.

Authors:  J Robert; M David; C Granger
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Authors:  K Mross; U Mayer; K Hamm; K Burk; D K Hossfeld
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Authors:  Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo A Maggi; Stefano Manzini; Giorgio Minotti
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

Authors:  W J van der Vijgh; P A Maessen; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.

Authors:  R L Schilsky; M J Ratain; L Janisch; N J Vogelzang; V S Lucas; J Ravitch; J A Hohneker; N J Clendeninn; R L Tuttle
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

8.  Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.

Authors:  C J Twelves; N A Dobbs; Y Michael; L A Summers; W Gregory; P G Harper; R D Rubens; M A Richards
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.